Cancer is not just a pile of rogue cells - it is a game where your immune system has already been throwing elbows long before the oncologist walks onto the field. This new Immunity paper suggests that in some untreated human tumors, the immune system has already knocked a bunch of the most visible cancer clones off the scoreboard. Not cured, obviously. More like the tumor made the playoffs by benching the players most likely to get tackled.
That idea is called immunoediting, and if you have not met it before, it is one of cancer biology's more devious plot twists. The immune system does not merely attack tumors. It can also shape which tumor cells survive. In other words, cancer evolves under pressure, a bit like bacteria under antibiotics, except with more betrayal and worse branding.
The tumor had options, and chose stealth
The study looked at primary, treatment-naive cutaneous squamous cell carcinoma - a common skin cancer - from both immunocompetent patients and immunosuppressed patients. That comparison matters because it gives scientists a natural experiment. If the immune system is really shaping tumors, then tumors growing in people with stronger immune surveillance should look different from tumors growing where that surveillance is weaker.
And that is pretty much what the authors found.
Tumors with high immune infiltrates in immunocompetent patients had lower overall mutational burden and, more specifically, lower clonal mutational burden than low-infiltrate tumors and tumors from immunosuppressed patients. "Clonal" means mutations shared by most or all cancer cells - the trunk of the tumor's family tree, not the weird cousin branches that show up later.
That is the key point. If the immune system preferentially eliminates cells carrying the most immunogenic mutations early on, then those mutations should be less likely to become clonal. The paper found exactly that pattern.
Neoantigens: the tumor's fake mustache slips
A neoantigen is basically a mutation-created molecular flag that can appear foreign to T cells. These are the features that make cancer cells stand out, at least when the immune system can still get a good look. Think of neoantigens as the tumor's terrible disguise failing under bright lighting. "Hello fellow normal cells," says the cancer clone, while wearing a fake nose from a party store.
The authors showed that predicted MHC class I-binding neoantigens became less common as the variant allele frequency increased. Translation: the mutations most capable of producing immune-visible targets were less likely to dominate the tumor. In high-immune-infiltrate tumors from immunocompetent patients, neoantigens resembling known immunogenic ones were especially depleted in clonal compared with subclonal populations.
That is a strong sign that the immune system is not just present - it has been editing the cast list.
This matters way beyond skin cancer
Cutaneous squamous cell carcinoma is a useful place to see this because it often carries lots of UV-induced mutations, which means lots of chances to generate neoantigens. But the broader idea travels well. Melanoma, lung cancer, bladder cancer, even mismatch repair-deficient tumors all live on some version of this same evolutionary chessboard, where the immune system rewards invisibility and punishes flamboyance.
Nature keeps doing this across systems. Predators shape camouflage in moths. Antibiotics shape resistant bacteria. Human immunity appears to shape which cancer clones get to stick around. Biology, as usual, keeps reusing the same script with different costumes.
That also helps explain one of the annoying truths about immunotherapy: the tumors most vulnerable to immune attack may already have lost some of their easiest-to-see targets by the time we meet them. By then, the obvious criminals may have fled, leaving behind the quieter ones who know not to post their crimes online.
Why this is exciting - and why it is annoying
This study gives unusually direct evidence in untreated human tumors that immunoediting is happening before therapy begins. That matters because a lot of the field's strongest evidence has come from mouse models or from tumors after treatment pressure. Here, the editing seems to be part of the natural history of the cancer itself.
If this finding holds up and expands to other cancers, it could affect how we think about:
- Who responds to immunotherapy
- Which neoantigens make the best vaccine targets
- Why some tumors look inflamed but still escape
- How early immune pressure shapes later resistance
It may also push researchers to focus less on raw mutation counts and more on which mutations survive clonally. Not every mutation matters equally. Some are just genomic confetti. Others wave giant flags at T cells and get edited out before they can anchor the tumor population.
The annoying part, of course, is that cancer keeps learning. Elephants solved part of their cancer problem by stockpiling extra tumor-suppressor tools. Humans, meanwhile, get a skin tumor that apparently learns selective invisibility before we even start treatment. Great. Love that for us.
The bigger takeaway
This paper makes tumors look less like static lumps and more like ecosystems under active surveillance. The immune system is not only fighting cancer - it is helping decide which cancer cells are allowed to remain. That does not mean immunity always wins. Clearly not. But it may change the lineup before the final buzzer.
And that is the weirdly hopeful part. If we can understand what got edited out, what slipped through, and why, we may get better at designing therapies that expose the clones still hiding in plain sight.
References
-
Borden ES, Castellano D, Kantzos EA, et al. Immunoediting restricts clonal neoantigens in primary, treatment-naive human tumors. Immunity. 2026;S1074-7613(26):00505-X. doi:10.1016/j.immuni.2026.05.005
-
O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151-167. doi:10.1038/s41571-018-0142-8
-
McGranahan N, Swanton C. Neoantigen quality, clonal heterogeneity, and immune escape in cancer evolution. Cell. 2019;179(2):219-221. doi:10.1016/j.cell.2019.09.028
-
Łuksza M, Riaz N, Makarov V, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2022;604(7904):517-522. doi:10.1038/s41586-022-04572-w
-
Schumacher TN, Thommen DS. T cell dysfunction in cancer. Cancer Cell. 2022;40(4):404-417. doi:10.1016/j.ccell.2022.03.012
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.